Study Phase 3

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)

Trial Information

Generic NameNiraparib and Abiraterone AcetateProduct NameAKEEGA®Therapeutic AreaAntineoplastic and Immunomodulating AgentsProduct ClassAntineoplastic AgentsPharmacological SubgroupOther Antineoplastic AgentsChemical SubgroupPoly (ADP-Ribose) Polymerase (PARP) InhibitorsCondition StudiedNeoplasms, Prostatic
Sponsor Protocol Number64091742PCR3001Enrollment765Data PartnerJohnson & Johnson% Female0.0%Mean/Median Age (Years)69.7% White70.3%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.